Seeger Weiss partners lead National Prescription Opiate Litigation Plaintiffs’ Executive Committee in $26 billion global opioid settlement

Seeger Weiss founding partner Chris Seeger along with partners Jennifer Scullion and Dave Buchanan helped lead the National Prescription Opiate Litigation team that resulted in over 90 percent of litigating local governments confirming participation in global settlements with AmerisourceBergen, Cardinal Health, and McKesson, and Johnson & Johnson totaling $26 billion. The settlements require 85% of […]

March 3, 2022

Seeger Weiss founding partner Chris Seeger along with partners Jennifer Scullion and Dave Buchanan helped lead the National Prescription Opiate Litigation team that resulted in over 90 percent of litigating local governments confirming participation in global settlements with AmerisourceBergen, Cardinal Health, and McKesson, and Johnson & Johnson totaling $26 billion.

The settlements require 85% of funds be allocated to programs that will help address the ongoing opioid crisis through treatment, education, and prevention efforts. A majority of states have already passed agreements that dictate how funds will be distributed between state and local subdivision governments, ensuring funds will effectively reach communities in the coming months. The first round of funding could be delivered as soon as May 2022 following a consent judgment within each participating state. The settlement also calls for injunctive relief that requires the “Big Three” drug distributors and Johnson & Johnson to make significant changes to corporate practices to protect consumer health and welfare.

The settlement was made possible in part by the years of advocacy by the entire Plaintiffs’ Executive Committee (PEC) on behalf of their more than 3,300 community clients. This team of lawyers worked for over four years to position these cases for this unprecedented resolution and cultivated collaborative working relationships with the State Attorneys General. The Plaintiffs’ Executive Committee continues to work actively with all parties to address the unique needs of the few states and communities that have yet to sign onto the agreements.

In addition to Seeger Weiss, the PEC negotiation team also included Elizabeth Cabraser of Lieff Cabraser, Jayne Conroy of Simmons Hanly Conroy, Paul Geller of Robbins Geller, Peter Mougey of Levin Papantonio Rafferty, and Joe Rice of Motley Rice LLC. Collectively they issued the following statement on February 25, 2022 regarding the acceptance of the settlements:

“We arrived at this moment after years of work by community leaders across the country who committed themselves to seeking funds they need to combat the opioid epidemic. We must also recognize the efforts of the many attorneys general and private counsel who have relentlessly pursued long overdue opioid epidemic recovery resources on behalf of their constituents and clients. The bottom line from this news is that help is on the way for first responders and healthcare workers on the front lines of this public health crisis. While nothing can truly make whole what was lost in this country, what we can do is ensure that thousands of communities nationwide have the tools they need to prevent the opioid epidemic from taking more lives. We hope this agreement does exactly that. It is also important to remember that while this is a vital step, it is only one of the many that are necessary to put an end to this crisis. We will continue our work at the negotiation table and in court during the trials ahead to hold companies in the opioid supply chain accountable.”

The settlement is the first of its kind to administer resources directly to the state and local governments specifically for relief programs to help rebuild the devastation caused by the opioid epidemic. The settlement will distribute funds based on population adjusted for the proportionate share of the opioid epidemic impact. The share of the impact is calculated using detailed, and objective national data, including the amount of opioids shipped to the state, the number of opioid-related deaths that occurred in the state and the number of people who suffer opioid use disorder in the state.

Updated information about these settlements are available at the Plaintiffs’ Executive Committee negotiation team’s website: www.nationalopioidsettlement.com.

Related News

October 30, 2026
Seeger Weiss Named Litigation Department of the Year for Products Liability and Mass Torts at the 2026 New Jersey Legal Awards

New Jersey-based Seeger Weiss has been named Litigation Department of the Year in the Products Liability and Mass Torts category at the New Jersey Law Journal’s 2026 New Jersey Legal Awards. Winners were announced on October 29, 2026, at The Palace at Somerset Park in Somerset, New Jersey. Over the past year, the department took […]

Read More
October 25, 2026
Seeger Weiss Partner Christopher A. Seeger Receives Inaugural Monroe E. Price Award from the Benjamin N. Cardozo School of Law

Seeger Weiss Partner Christopher Seeger received the inaugural Monroe E. Price Award from the Benjamin N. Cardozo School of Law, his alma mater, at the school’s 50th Anniversary Gala at the Hall des Lumières in New York City on October 22, 2026. The award is named for Monroe Price, who served as Dean of Cardozo […]

Read More
October 23, 2026
Seeger Weiss’s Christopher A. Seeger Appointed Co-Lead Counsel in In re: Dupixent (Dupilumab) Products Liability Litigation

Seeger Weiss LLP is pleased to announce that Partner Christopher A. Seeger has been appointed Co-Lead Counsel in In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, pending in the U.S. District Court for the District of New Jersey. The litigation involves claims that Dupixent, an injectable biologic prescribed to treat inflammatory conditions including […]

Read More
↑